Time for public debate, says gene editing star Jennifer Doudna – The San Diego Union-Tribune
The San Diego Union-Tribune |
Time for public debate, says gene editing star Jennifer Doudna
The San Diego Union-Tribune “It’s important to for people to appreciate that this is a powerful technology that has the potential to do a lot of good, to solve real world problems not only in clinical medicine but also in agriculture and synthetic biology,” Doudna said. Doudna … |
MIMS General News (Hong Kong) (registration) (blog) |
American scientists use CRISPR to modify human embryos
MIMS General News (Hong Kong) (registration) (blog) Led by embryologist, Dr Shoukhrat Mitalipov – a researcher at the university – the team used the gene-editing technique CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) to introduce gene-editing chemicals to single-cell embryos. |
CBS Philly |
Teen Battles Brain Cancer, Raises Money For Treatment
CBS Philly PHILADELPHIA (CBS) — This is a mission to raise money specifically for immunotherapy research. It’s been called a game changer, the next frontier in treating, even curing cancer. A New Jersey teenager is hoping a new immunotherapy works for him and … |
Surrey Now-Leader |
Drive for stem cell donors in Langley
Surrey Now-Leader More than 390,000 Canadians have joined the OneMatch Stem Cell and Marrow Network registry maintained by Canadian Blood Services, volunteering to be stem cell donors for any patient in need of a transplant, anywhere in the world. Right now, the … Surrey teen rallies stem cell donors to help with ‘desperate’ need for South AsiansLangley Times |
|
Cost-effectiveness of allergen immunotherapy evaluated
Medical Xpress … the researchers found that sublingual immunotherapy (SLIT) and subcutaneous immunotherapy would be considered cost-effective using the U.K. National Institute for Health and Clinical Excellence threshold of £20,000/quality-adjusted life-year (QALY). |
Lymphoma Hub |
CLL post-ibrutinib: CAR T-cell therapy shown to result in durable molecular remissions
Lymphoma Hub Use of anti-CD19 Chimeric Antigen Receptor (CAR) T-cell therapy in CLL previously treated with ibrutinib has recently been shown to induce ‘durable molecular remissions’ in a phase I/II open-label study. The study, published in the Journal of Clinical … |